Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Life Science Institute Launches Clinical Study of IV Regenerative Medicine Product for Acute Myocardial Infarction
January 18, 2018
- Kyowa Kirin Officially Announces Launch of Japan’s 1st Rituxan Biosimilar on Jan. 18
January 18, 2018
- Mitsubishi Tanabe Grabs Add’l Indication for Novastan in China
January 17, 2018
- Toray Grants China License for Remitch OD to 3SBio
January 17, 2018
- Nichi-Iko Teams Up with 2 Philippine Companies
January 17, 2018
- Ethical Drug Sales Up 0.8% in November on Cancer Meds
January 17, 2018
- Nissui Pharmaceutical Invests 50 Million Yen in Regenerative Medicine Startup
January 16, 2018
- Repatha Auto Mini Doser Now Available in Japan
January 16, 2018
- Opdivo-Yervoy Combo Filed for RCC in Japan
January 16, 2018
- Japan’s 1st Rituxan Biosimilar to Hit Shelves as Scheduled despite Patent Suit Filed
January 16, 2018
- Janssen, NCNP Link Arms to Develop Biomarkers for Predicting Schizophrenia Risk
January 16, 2018
- JT/Torii’s JAK Inhibitor Delivers Positive PIII Data
January 15, 2018
- Takecab Most Promoted Drug for Hospital Doctors for 12 Months on End
January 15, 2018
- Eisai’s Oral Solid Dose Facility Completed in China
January 12, 2018
- Nippon Chemiphar’s Antidepressant Candidate Selected for AMED’s CiCLE Grant Program
January 12, 2018
- Suglat Filed for Type 1 Diabetes in Japan: Astellas/Kotobuki
January 12, 2018
- Will Symbicort and Adoair Face Generic Entries This Year? Trade Group Has Seen High Hurdle for Inhaler Drugs
January 11, 2018
- DeNA in AI Joint Research Pact with Asahi Kasei, Shionogi
January 11, 2018
- Shionogi Gains Access to US Startup’s Drug Discovery Platform
January 11, 2018
- Talion Authorized Generics to Launch on March 1
January 11, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…